ALL, MDS, Other Hematologic Malignant Neoplasms
Conditions
Brief summary
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Minor/Major Patients * Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. * No objection made or consent given
Exclusion criteria
* Patients under judicial protection (guardianship, curatorship, ...), * Refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer | 2021-2026 | identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH. |
Secondary
| Measure | Time frame |
|---|---|
| identification of new chromosomal abnormalities of clinical relevance. | 2021-2026 |
| identification of new chromosomal anomalies involved in oncogenic pathways | 2021-2026 |
Countries
France
Contacts
Primary ContactMarie-Bérengère, TROADEC, PhD
Backup ContactNathalie DOUET-GUILBERT, MD, PhD
Outcome results
None listed